Heron Therapeutics Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating reaffirmed by equities research analysts at JMP Securities in a research report issued to clients and investors on Wednesday.

A number of other research analysts also recently commented on HRTX. Jefferies Group reaffirmed a “buy” rating and issued a $46.00 price target on shares of Heron Therapeutics in a research note on Wednesday, July 27th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $41.00 price target on shares of Heron Therapeutics in a research note on Wednesday, August 3rd. Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Leerink Swann set a $33.00 price target on Heron Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 11th. Finally, Brean Capital reaffirmed a “buy” rating and issued a $55.00 price target on shares of Heron Therapeutics in a research note on Saturday, August 13th. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Heron Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $41.63.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) opened at 18.45 on Wednesday. The firm’s 50-day moving average is $16.29 and its 200-day moving average is $18.19. Heron Therapeutics has a 52-week low of $13.95 and a 52-week high of $31.32.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, November 8th. The biotechnology company reported ($1.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.17) by $0.07. Equities research analysts forecast that Heron Therapeutics will post ($4.39) EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock valued at $6,622,000 after buying an additional 19,737 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Heron Therapeutics during the first quarter valued at $734,000. Panagora Asset Management Inc. boosted its stake in Heron Therapeutics by 90.3% in the first quarter. Panagora Asset Management Inc. now owns 245,392 shares of the biotechnology company’s stock valued at $4,660,000 after buying an additional 116,461 shares during the period. Cormorant Asset Management LLC boosted its stake in Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock valued at $33,233,000 after buying an additional 64,281 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Heron Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 147,986 shares of the biotechnology company’s stock valued at $2,672,000 after buying an additional 4,579 shares during the period.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.